Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

1 Green Flag and 1 Red Flag for Provention Bio

TheMotleyFool

0 0

1 Green Flag and 1 Red Flag for Provention Bio: https://g.foolcdn.com/editorial/images/701554/doctor-with-patient-talking.jpg

Things can change quickly in the volatile biotech industry. Just ask Provention Bio (NASDAQ: PRVB). The autoimmune disease-focused drugmaker seemed on the verge of earning a major regulatory approval for its leading candidate, teplizumab, in early 2021. However, because of regulatory roadblocks, the drugmaker has yet to win the green light from regulators for this therapy.

The headwinds related to teplizumab have played a critical role in Provention Bio's poor performance over the past 18 months, but could the biotech turn the tide? Let's consider one reason Provention Bio's stock could soar relatively soon and one reason to worry.

Source Fool.com

Like: 0

PRVB

Share